What is Biogen's qalsody japan — research and development:?

Biogen (BIIB) reported qalsody japan — research and development: of $2.50M in Q4 2024.

What does qalsody japan — research and development: mean?

The total amount spent on research and development activities for the QALSODY product in Japan.

Discontinued — last reported Q4 '24

Products & Services · Research and development:

QALSODY Japan — Research and development:

Biogen QALSODY Japan — Research and development: remained flat by 0.0% to $2.50M in Q4 2024 compared to the prior quarter.

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ1 2024

Last reportedQ4 2024

Rolls up toR&D

How to read this metric

An increase suggests intensified investment in clinical development or regulatory support for the product in Japan, while a decrease may indicate a shift in strategy or the completion of key development milestones.

Detailed definition

This metric represents the direct financial investment allocated to research and development activities specifically ass...

Peer comparison

Comparable to regional R&D expense line items reported by other global pharmaceutical companies for specific drug launches or localized clinical programs.

Metric ID: biib_segment_qalsody_japan_research_and_development

Historical Data

1 years

	FY'24
Value	$10.00M

Similar Metrics at Other Companies

IQVIAIQV View metric

AmgenAMGN View metric

IQVIAIQV View metric

Becton, Dickinson and CompanyBDX View metric

Frequently Asked Questions

What is Biogen's qalsody japan — research and development:?: Biogen (BIIB) reported qalsody japan — research and development: of $2.50M in Q4 2024.
What does qalsody japan — research and development: mean?: The total amount spent on research and development activities for the QALSODY product in Japan.